Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Managing ovarian toxicity with varegacestat in women with desmoid tumors

Piotr Rutkowski, MD, PhD, Curie National Research Institute, Warsaw, Poland, comments the ovarian toxicity profile of varegacestat in young women with desmoid tumors in the Phase III RINGSIDE (NCT04871282) trial. Informed consent is essential regarding potential amenorrhea and permanent dysfunction risks, despite the clinical benefits of gamma secretase inhibitors in patients with progressive, poorly located desmoid tumors causing significant morbidity and pain. He recommends careful patient selection, limiting treatment to those with genuine clinical need, and suggests considering oncofertility preservation for young women prior to initiating therapy, while acknowledging that hormonal dysfunction remains an inevitable side effect. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

We haven’t super long data on the ovarian toxicity in some patients. But although 57 % of young women were affected by ovaria dysfunction. But this patient who stopped Varegacestat treatment, the ova function again returned. So this is something that is very positive. However, many of the patients are still on treatment. And they have amenorrhea. We don’t know if it is permanent or not...

We haven’t super long data on the ovarian toxicity in some patients. But although 57 % of young women were affected by ovaria dysfunction. But this patient who stopped Varegacestat treatment, the ova function again returned. So this is something that is very positive. However, many of the patients are still on treatment. And they have amenorrhea. We don’t know if it is permanent or not. But of course, this is something that should be carefully described to the patient and discussed with the young. We mean that we can induce this dysfunction. And we are not sure if it’s permanent or no. For Varegacestat, there was some permanent dysfunction. Here, we don’t, as I said, this patient who stopped the treatment. They regained the function of the ovarian. So generally, of course, we do not try to over-treat the patient with gamma secretase inhibitors. We treat only the patients who really need it. And this patient with very badly located progressive desmoid, like intra-abdominal, head and neck. But even extremities which are leading to the high morbidity and dysfunction and the pain. One of the results which we observe, for example, is better sleep after Varegacestat Because the pain was so painful for the patients. So generally, of course, this is what we should discuss. And probably, the preservation of the oncofertility preservation should be done in these women. Maybe this is a very good idea for young ladies. But of course… This is not the only dysfunction because it’s generally dysfunction which can lead also to the hormone dysfunction. So generally, we can monitor this because it has been done in the trial. But this is one of the side effects which is inevitable for this treatment.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.